Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Highlights - Adjuvant platinum-based chemotherapy is accepted as standard of care in stage II and III (NSCLC) patients - Several studies addressed the question whether molecular tumor markers may serve as predictive biomarkers - ITACA was planned to evaluate the predictive utility of ERCC1 and TS mRNA expression levels in completely resected NSCLC - ITACA results indicate that adjuvant chemotherapy customization based on ERCC1 and TS mRNA levels did not improve efficacy - In terms of safety,...
Reply to the letter to the editor ‘A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma’ by Hines et al. G. Rosati1, P. Mosconi2, V. Torri2, G. Apolone3, F. E. Johnson4 and R. Fossati2,* 1Department of Oncology, Ospedale San Carlo, Potenza 2Department of Oncology, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan 3Department of Oncology, IRCCS Arcispedale S.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
